Environmental factors associated with biological use and surgery in inflammatory bowel disease

Background and Aim: While major efforts were made studying the complex etiology of inflammatory bowel disease (IBD) including environmental factors, less is known about underlying causes leading to the heterogeneous and highly variable course of disease. As cigarette smoking cessation is the best-known environmental factor with beneficial effect in Crohn's disease (CD), more exposome factors are likely involved. Further insights into the role of the exposome in heterogeneity of disease might not only further knowledge of underlying pathways, but also allow for better risk stratification. Methods: Seven hundred twenty-eight IBD patients completed the validated Groningen IBD Environmental Questionnaire, collecting exposome data for 93 exposome factors. Associations with disease course, that is, for need for surgery or biological therapy, were evaluated using univariate and multivariate-adjusted logistic regression modeling. Results: No significant associations were seen after Bonferroni correction. However, 11 novel exposome factors were identified with P &lt; 0.05. Two factors were associated with course of CD and ulcerative colitis (UC): beer (CD OR0.3/UC OR0.3) and cannabis (0.5/2.2). While in CD, carpet flooring (0.5) was associated with biological use, and four factors were associated with surgery: working shifts (1.8), appendectomy (2.4), frequent tooth brushing (2.8), and large household size (0.1). For UC, migrants more often required biologicals (10.2). Childhood underweight (3.4), amphetamine use (6.2), and cocaine use (4.8) were associated with surgery. Five factors were replicated. Conclusions: We identified 16 environmental factors nominally associated with biological use and surgery in established IBD. These new insights form an important stepping stone to guide research on biological pathways involved, risk stratification, tailor-made interventions, and preventive strategies in IBD.</p

Prophylaxis with ertapenem in patients with obstructive jaundice undergoing endoscopic retrograde cholangiopancreatography: safety, efficacy, and biliary penetration.

Aldridge KE, 2002, DIAGN MICR INFEC DIS, V44, P181, DOI 10.1016-S0732-8893(02)00430-3; BROWN RB, 1976, ANN INTERN MED, V84, P168; Cotton PB, 2008, GASTROINTEST ENDOSC, V67, P471, DOI 10.1016-j.gie.2007.06.065; Deviere J, 2008, NAT CLIN PRACT GASTR, V5, P594, DOI 10.1038-ncpgasthep1262; Dhalluin-Venier V, 2008, EUR J GASTROEN HEPAT, V20, P127, DOI 10.1097-MEG.0b013e3282f1c985; Friedland I, 2002, J CHEMOTHERAPY, V14, P483; Fuchs PC, 2001, ANTIMICROB AGENTS CH, V45, P1915, DOI 10.1128-AAC.45.6.1915-1918.2001; Graham DR, 2002, CLIN INFECT DIS, V34, P1460, DOI 10.1086-340348; Harris A, 1999, ENDOSCOPY, V31, P718, DOI 10.1055-s-1999-153; Jimenez-Cruz F, 2002, UROLOGY, V60, P16, DOI 10.1016-S0090-4295(02)01664-3; Lau JYW, 1996, BRIT J SURG, V83, P181; LEUNG JWC, 1992, ANTIMICROB AGENTS CH, V36, P2057; LEUNG JWC, 1994, GASTROINTEST ENDOSC, V40, P716; Llach J, 2006, HEPATO-GASTROENTEROL, V53, P540; Majumdar AK, 2002, ANTIMICROB AGENTS CH, V46, P3506, DOI 10.1128-AAC.46.11.3506-3511.2002; MOLLISON LC, 1994, J GASTROEN HEPATOL, V9, P55, DOI 10.1111-j.1440-1746.1994.tb01216.x; NIEDERAU C, 1994, GASTROINTEST ENDOSC, V40, P533; Ortiz-Ruiz G, 2002, CLIN INFECT DIS, V34, P1076; Rey JR, 1998, ENDOSCOPY, V30, P318; Roy Subir, 2003, Infect Dis Obstet Gynecol, V11, P27, DOI 10.1155-S1064744903000048; Smith BC, 1996, J GASTROEN HEPATOL, V11, P938; Solomkin JS, 2003, ANN SURG, V237, P235, DOI 10.1097-00000658-200302000-00013; Tomera KM, 2002, ANTIMICROB AGENTS CH, V46, P2895, DOI 10.1128-AAC.46.9.2895-2900.2002; vandenHazel SJ, 1996, ANN INTERN MED, V125, P442; Vetter N, 2002, CLIN THER, V24, P1770, DOI 10.1016-S0149-2918(02)80078-9; Wittau M, 2006, J ANTIMICROB CHEMOTH, V57, P312, DOI 10.1093-jac-dki459; Yamamoto S, 2002, HEPATO-GASTROENTEROL, V49, P33033